Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Shares Outstanding (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Shares Outstanding for 5 consecutive years, with $638558.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding fell 93.17% year-over-year to $638558.0, compared with a TTM value of $638558.0 through Dec 2025, down 93.17%, and an annual FY2025 reading of $638558.0, down 93.17% over the prior year.
  • Shares Outstanding was $47.7 million for Q4 2025 at SAB Biotherapeutics, up from $638558.0 in the prior quarter.
  • Across five years, Shares Outstanding topped out at $47.7 million in Q4 2025 and bottomed at -$546658.0 in Q2 2022.
  • Average Shares Outstanding over 5 years is $12.3 million, with a median of $4.7 million recorded in 2021.
  • The sharpest move saw Shares Outstanding plummeted 102.1% in 2022, then surged 22028.9% in 2025.
  • Year by year, Shares Outstanding stood at $26.0 million in 2021, then plummeted by 80.39% to $5.1 million in 2022, then soared by 82.18% to $9.3 million in 2023, then grew by 0.68% to $9.3 million in 2024, then plummeted by 93.17% to $638558.0 in 2025.
  • Business Quant data shows Shares Outstanding for SABS at $638558.0 in Q4 2025, $29091.0 in Q3 2025, and $9.3 million in Q2 2025.